more

Johnson & Johnson (JNJ)

(Real Time Quote from BATS)

$160.76 USD

+1.07 (0.67%)

Updated Oct 9, 2024 01:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5 4

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

Top 13% (33 out of 252)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Alkermes (ALKS) Q2 Earnings & Revenues Beat Estimates

by Zacks Equity Research Published on July 27,2023

Alkermes (ALKS) reports encouraging second-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol.

Fed's July Rate Hike and Comments Match Expectations: 5 Picks

by Nalak Das Published on July 27,2023

We have narrowed our search to five U.S. corporate behemoths. These are: META, GOOGL, ISRG, JNJ, PEP.

3 Top Blue Chip Stocks to Ride the Dow Rally

by Tirthankar Chakraborty Published on July 27,2023

As the Dow continues to scale upward, it's prudent to invest in stocks such as JPMorgan (JPM), Walmart (WMT) and Johnson & Johnson (JNJ) that are listed on the said index and are financially sound.

Dow Jones ETFs Continue Winning Run as Rates at 2001 High

by Sanghamitra Saha Published on July 27,2023

Fed raised its benchmark interest rate by 0.25% on Wednesday, leaving room for more hikes this year. Such rising rate environment is a plus for the Dow Jones ETFs.

etfs

The Zacks Analyst Blog Highlights Johnson & Johnson, Zoetis, Lam Research, Aon and Dominion Energy

by Zacks Equity Research Published on July 27,2023

Johnson & Johnson, Zoetis, Lam Research, Aon and Dominion Energy are included in this Analyst Blog.

pharmaceuticals

Top Analyst Reports for Johnson & Johnson, Zoetis & Lam Research

by Sheraz Mian Published on July 26,2023

Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Zoetis (ZTS) and Lam Research Corporation (LRCX).

GSK Beats on Q2 Earnings & Sales, Raises 2023 Guidance

by Zacks Equity Research Published on July 26,2023

GSK's revenues benefit from strong growth across all segments, especially HIV and vaccine. GSK raises guidance for earnings and sales. Shares rise in pre-market trading post the announcement.

Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term

by Zacks Equity Research Published on July 26,2023

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

JNJPositive Net Change

Bayer (BAYRY) Cuts 2023 Outlook, Reports Preliminary Q2 Results

by Zacks Equity Research Published on July 26,2023

Bayer (BAYRY) lowers its full-year financial performance guidance for 2023 and reports preliminary earnings results for the second quarter of 2023.

biotechs

4 Stocks to Buy Following Beat-and-Raise Quarters

by Derek Lewis Published on July 25,2023

These companies beat expectations and raised their outlooks, undeniably a positive sign for investors. Is it time to buy following the better-than-expected results?

Will AbbVie's (ABBV) New Drugs Make Up for Low Humira Sales?

by Zacks Equity Research Published on July 25,2023

In its Q2 earnings results, AbbVie's (ABBV) Skyrizi and Rinvoq sales are expected to have made up for the declining Humira sales following the loss of U.S. exclusivity.

Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research Published on July 25,2023

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

JNJPositive Net Change

3 Reasons Why Growth Investors Shouldn't Overlook Johnson & Johnson (JNJ)

by Zacks Equity Research Published on July 24,2023

Johnson & Johnson (JNJ) possesses solid growth attributes, which could help it handily outperform the market.

JNJPositive Net Change

Are You Looking for a High-Growth Dividend Stock?

by Zacks Equity Research Published on July 24,2023

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

JNJPositive Net Change

AbbVie (ABBV) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research Published on July 21,2023

AbbVie's (ABBV) Q2 performance will likely reflect Skyrizi and Rinvoq sales trying to make up for the declining Humira sales following the loss of U.S. exclusivity.